top of page
IROCK collaborates on research into stereotactic ablative radiotherapy (SABR) for primary renal cell carcinoma (RCC).
The primary purpose of the IROCK Registry is to evaluate the time between SABR treatment and recurrence (when cancer returns after treatment) in patients with RCC. Secondary objectives of the registry will assess efficacy and survival outcomes.
​
The registry now has over 20 active sites globally, gathering patient data that will form the basis of our analyses.
The IROCK Registry is extremely grateful to the Lo's Family Charity Fund Limited
for providing the registry with secure funding for five years via a generous donation.
bottom of page